Main
/Trials
Study type: Immunotherapy
Study type: Targeted therapy
Found:
10 trials shown from 606 total

Astrazeneca

Key trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Estimated study start date: 23 November 2023

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investig

Study number:
NCT06103864
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Estimated study start date: 16 November 2023

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who r

Study number:
NCT05920356
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Chemotherapy, Targeted therapy

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Estimated study start date: 17 August 2023

This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab

Study number:
NCT06007937
Cohorts:
1
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Biomarker, Targeted therapy

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

Estimated study start date: 1 August 2023

The objective of this study is to determine overall response rate to combination of S-1 and Osimertinib in treatment-resistant EGFR mutant lung cancer.

Study number:
NCT05773092
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Targeted therapy

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Estimated study start date: 18 July 2023

This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Loca

Study number:
NCT05801029
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Targeted therapy

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Estimated study start date: 27 June 2023

This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.

Study number:
NCT05883644
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Immunotherapy

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Estimated study start date: 7 June 2023

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulv

Study number:
NCT05646862
Cohorts:
1
Study phase:
3
Overall status:
Not yet recruiting
Study type:
Targeted therapy, Hormonal therapy

AMAZE-lung: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Estimated study start date: 27 March 2023

AMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given in a three-weekly regimen. The p

Study number:
NCT05601973
Cohorts:
1
Study phase:
2
Overall status:
Recruiting
Study type:
Targeted therapy, Chemotherapy

Novartis

Key trial

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Estimated study start date: 28 February 2023

Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890

Study number:
NCT05552469
Cohorts:
1
Study phase:
1
Overall status:
Not yet recruiting
Study type:
Targeted therapy

Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

Estimated study start date: 28 February 2023

Hepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficac

Study number:
NCT05516628
Cohorts:
1
Study phase:
2
Overall status:
Not yet recruiting
Study type:
Local/Regional therapies, Immunotherapy